HuGE Literature Finder
Records
1
-
7
| Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
| Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. ESMO open 2021 Mar 6 (2): 100062. Sastre J, García-Alfonso P, Viéitez J M, Cano M T, Rivera F, Reina-Zoilo J J, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont M J, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López R L, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E, |
| Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. Scientific reports 2021 7 11 (1): 14321. Fernández Montes Ana, Carmona-Bayonas Alberto, Jimenez-Fonseca Paula, Vázquez Rivera Francisca, Martinez Lago Nieves, Covela Rúa Marta, Cousillas Castiñeiras Antía, Gonzalez Villarroel Paula, De la Cámara Gómez Juan, Méndez José Carlos Méndez, Carriles Fernández Carmen, Sanchez Cánovas Manuel, Garcia García Tere |
| A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. British journal of cancer 2019 Jul . Elez Elena, Pericay Carles, Valladares-Ayerbes Manuel, Bando Inmaculada, Safont Maria Jose, Gallego Javier, Grávalos Cristina, Arrivi Antonio, Carrato Alfredo, Conde Verónica, Ortiz Maria José, López Carlos, Alonso Beatriz, Ruiz de Mena Inmaculada, Díaz-Rubio Eduardo, Tabernero Josep, Aranda Enriq |
| Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. The Lancet. Oncology 2016 Apr . Planchard David, Kim Tae Min, Mazieres Julien, Quoix Elisabeth, Riely Gregory, Barlesi Fabrice, Souquet Pierre-Jean, Smit Egbert F, Groen Harry J M, Kelly Ronan J, Cho B C, Socinski Mark A, Pandite Lini, Nase Christine, Ma Bo, D'Amelio Anthony, Mookerjee Bijoyesh, Curtis C Martin, Johnson Bruce |
| FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Aug 24 (8): 2062-7. Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone |
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England) 2012 Jul 380 (9839): 358-65. Hauschild Axel, Grob Jean-Jacques, Demidov Lev V, Jouary Thomas, Gutzmer Ralf, Millward Michael, Rutkowski Piotr, Blank Christian U, Miller Wilson H, Kaempgen Eckhart, Martín-Algarra Salvador, Karaszewska Boguslawa, Mauch Cornelia, Chiarion-Sileni Vanna, Martin Anne-Marie, Swann Suzanne, Haney Patricia, Mirakhur Beloo, Guckert Mary E, Goodman Vicki, Chapman Paul |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: